Ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia (RADIANCE)


March 1, 2014

Clinical trial

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.

Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M.

Ophthalmology. 2014 Mar;121(3):682-92.e2.
Full text | Metrics.

Share This Article :

Updated on March 7th, 2022

Source Archive